Inside the research
Integra LifeSciences Holdings Corporation
IART Research profile · latest available data
Price overview
$16.27
▲ +0.15 (+0.9%)
| 52w hi | $19.85 |
|---|---|
| 52w lo | $8.90 |
| Vol | 479.03K |
| As of | 28 Sep 2026 |
The Verdict
Our score -0.14
| Short | -0.21 |
|---|---|
| Medium | -0.04 |
| Long | -0.20 |
computed 2026-09-28
Key fundamentals
Integra LifeSciences Holdings Corporation
Healthcare · Medical Devices
| Market cap | $1.27B |
|---|---|
| Enterprise value | $3.03B |
| Forward P/E | 6.24x |
| EV / EBITDA | 9.56x |
| P / S (ttm) | 0.77x |
| Profit margin | -0.4% |
| Return on equity | -0.7% |
| Revenue growth | +0.8% |
| Debt / equity | 196.49 |
Layer Breakdown
| Layer | Raw | Contribution |
|---|---|---|
| Fundamental | +0.06 | |
| Sector | +0.09 | |
| Technical | -0.16 | |
| Earnings | +0.00 | |
| Sentiment | +0.00 |
macro × 1.00 · 2026-09-28
Business overview
Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical, ear, nose, throat, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates through Codman Specialty Surgical and Tissue Technologies segments. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment. It also offers after-market services; surgical headlamps and instrumentation; instrument patterns and surgical and lighting products to hospitals, surgery centers, dental, podiatry, and veterinary offices. In addition, the company provides treatment of acute wounds, such as burns; chronic wounds, including diabetic foot ulcers; and surgical tissue repair applications, including hernia reinforcement, tendon protection, and peripheral nerve repair. Further, it offers skin and wound repair, plastics and surgical reconstruction products, and nerve and tendon repair products. Additionally, the company is involved in the ear, nose, and throat business that includes instrumentation, balloon technologies for sinus dilation and eustachian tube dilation, and surgical navigation systems. It offers its products directly through various salesforces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, the Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was formerly known as Integra LifeSciences Corp. and changed its name to Integra LifeSciences Holdings Corporation in June 1995. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.
Risk Metrics
| Beta vs SPX | 1.45 |
|---|---|
| Corr SPX | 0.38 |
| Annual vol | 60.9% |
| Annual ret | +14.8% |
| Sharpe | 0.24 |
| Max DD | -66.7% |
Window: 504 trading days (504 obs)
Material Events
| Date | Event | 8-K |
|---|---|---|
| 2026-07-29 | Earnings Release, Exhibits | read |
| 2026-05-08 | Officer / Director Change, Shareholder Vote… | read |
| 2026-05-05 | Officer / Director Change, Exhibits | read |
| 2026-05-05 | Earnings Release, Exhibits | read |
| 2026-04-15 | Material Agreement | read |
| 2026-02-26 | Earnings Release, Exhibits | read |
| 2025-12-12 | Officer / Director Change, Exhibits | read |
| 2025-10-30 | Earnings Release, Exhibits | read |
| 2025-07-31 | Earnings Release, Exhibits | read |
| 2025-06-09 | Material Agreement, Material Obligation… | read |
| 2025-05-13 | Officer / Director Change, Shareholder Vote… | read |
| 2025-05-05 | Earnings Release, Exhibits | read |
Insider Trades
| Date | Insider | Role | Action | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-03 | Knight Lea Daniels | EVP & Chief Financial Off | Withheld for tax | 5.23K | $94.33K |
| 2026-07-01 | Mosebrook Jeffrey | SVP, Fin & Princ Acct Off | Withheld for tax | 937 | $16.76K |
| 2026-05-09 | BRADLEY KEITH | Withheld for tax | 882 | $12.28K | |
| 2026-05-07 | HILL BARBARA B | Grant | 6.64K | — | |
| 2026-05-07 | HILL BARBARA B | Grant | 17.70K | — |
Flow & Concentration
| Insider 180d net | $0 |
|---|---|
| Insider buys / sells | 0 / 0 |
| Insider bias | Neutral |
| 13F holders | 7 |
| Top-5 share | 99.9% |
| HHI | 4,708 (concentrated) |
Top Holders
| Holder | Value | Shares |
|---|---|---|
| State Street Corp | $52.93M | 2.95M |
| Millennium Management | $25.86M | 1.44M |
| AQR Capital Management | $4.64M | 258.16K |
| Capital Research / Capital World | $2.48M | 138.32K |
| Renaissance Technologies | $188.58K | 10.50K |
| Fidelity / FMR LLC | $92.33K | 5.14K |
| T. Rowe Price Group | $1.65K | 91.92K |
As of 2026-06-30
SEC Filings
The Long Run
FY 2010–2025 · 16 years
| Line | Latest | CAGR | Trend |
|---|---|---|---|
| Revenue | $1.61B | +5.4% | |
| Gross profit | $230.78M | +7.9% | |
| Operating income | -$493.37M | +7.6% | |
| Net income | -$516.47M | +10.2% | |
| Cash from ops | $50.38M | -2.4% |
Indices
Recent Sessions
| Date | Open | High | Low | Close | Vol |
|---|---|---|---|---|---|
| Sep 28 | $15.99 | $16.27 | $15.86 | $16.27 | 479.03K |
| Sep 25 | $15.88 | $16.21 | $15.74 | $16.12 | 539.00K |
| Sep 24 | $15.67 | $15.91 | $15.49 | $15.88 | 759.50K |
| Sep 23 | $15.88 | $16.26 | $15.38 | $15.53 | 573.10K |
| Sep 22 | $15.90 | $16.29 | $15.69 | $16.02 | 770.50K |
Understand the score. Research layers are inputs to a model, and the available data has limits.
Read the methodology →